Research programme: alkaloid-conjugate analgesics - Chimeracom

Drug Profile

Research programme: alkaloid-conjugate analgesics - Chimeracom

Alternative Names: Chimeric hybrid molecules; Hybrid chimera

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chimeracom LLC
  • Class
  • Mechanism of Action Neurokinin 1 receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
  • 31 Oct 2007 Preclinical development is ongoing
  • 25 Aug 2005 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top